VenoStent has raised additional funding. Image courtesy of VenoStent

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

money moves

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston advance care company closes $7M funding round

fresh funding

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

TXSE Group wins SEC approval for Texas Stock Exchange to start in 2026

Trading in Texas

The U.S. Securities and Exchange Commission has given the go-ahead to the Dallas-based Texas Stock Exchange to operate as a national securities exchange, clearing the way for the TXSE to begin trading stocks and exchange-traded products by early 2026.

TXSE is the first fully integrated national securities exchange to receive SEC approval in decades. A release calls it "a milestone decision" that restores competition in America's public markets.

The organization has already laid the groundwork with an exchange platform utilizing the appropriate hardware and software that will function in an evolving trading and regulatory environment.

TXSE, which opened its headquarters in Dallas in spring 2025, will launch trading as well as ETP and corporate listings for companies that meet their standards and are fully transparent. Their goal is to compete with the NYSE and NASDAQ by building up a large roster of newly listed companies.

"Today's approval marks a pivotal moment in our effort to build a world-class exchange rooted in alignment, transparency, and partnership with issuers and investors," says TXSX founder and CEO James H Lee. "Real competition for corporate listings in the United States has finally arrived."

According to the release, TXSE's mission is to reverse a decades-long decline in the number of U.S. public companies by reducing the burden of going and staying public while maintaining high quantitative standards in the industry.

They've already pushed for legislative and legal reforms to strengthen Texas' pro-business environment and establish the state as the premier jurisdiction for corporate headquarters, listings, and exchange operators — working alongside Texas leadership to advocate on behalf of issuers and investors to reform policy.

"As the one and only national securities exchange built and headquartered in Texas, we are proud to have been the catalyst for the development of capital markets in our great state," Lee says.

TXSE's founding investors include financial institutions, retail, and institutional investment organizations, including BlackRock, Citadel Securities, and Charles Schwab, as well as major liquidity providers and corporate executives from across the U.S.

TXSE will be one of three exchanges to join Texas' so-called economic hub Y’all Street, along with the New York Stock Exchange and NASDAQ.

---

This article originally appeared on CultureMap.com.

10+ can't-miss Houston business and innovation events for October

where to be

Editor's note: Houston's October calendar is packed with informative and impactful events—plus a few fun ones, too. From the fourth annual Tejano Tech Summit to the first-ever Ion Family Tech Festival, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Oct. 3 — Houston Methodist Joy in Medicine Initiative Symposium

The Houston Methodist Joy in Medicine Initiative Symposium will explore the power of connection in enhancing professional fulfillment for clinicians and healthcare teams, this year under the theme “The Power of We.” Hear from Dr. Shlomit Schall, Houston Methodist Physician Organization president and CEO and chief physician executive, and Dr. J. Bryan Sexton, director of the Duke Center for Advancement and Well-being Science. Stick around for a networking happy hour.

This event is Friday, Oct. 3, from 8:30 a.m.-4:30 p.m. at the InterContinental Houston. Find more information here.

Oct. 6-10 — Surgical Technology & Robotic Surgery Summit (STaRS)

Surgeons, engineers, researchers and innovators can explore the latest advancements in surgical robotics, imaging and AI-integrated technologies at this year’s Surgical Technology & Robotic Surgery Summit. They can also take in the inaugural Surgical Technology & Robotic Surgery Innovator Competition. The summit will feature live demonstrations, interactive panels and cutting-edge research.

This event begins Monday, Oct. 6, at MITIE at The Bookout Center. Find more information here.

Oct. 7 — SUPERGirlsInSTEM Summit: The Intersection of AI & Workforce

The SUPERGirls SHINE Foundation presents its SUPERGirlsInSTEM Summit, where attendees can take part in open discussions, networking and workshops while learning about AI skills that can advance college studies and entry into the workforce.

This event is Tuesday, Oct. 7, from 9 a.m.-1 p.m. at the Ion. Find more information here.

Oct. 7 — Future of Health Care: Thought Leader Series

Hear from Rice University President Reginald DesRoches, and Kristen Doyle, CEO of the Cancer Prevention and Research Institute of Texas, at the Greater Houston Partnership’s Future of Health Care: Thought Leader Series. The expert panel will discuss key topics, including the proposed Dementia Prevention and Research Institute of Texas (DPRIT), Rice's Momentous strategic plan and "critical role of public health systems and cross-sector partnerships in advancing access, equity, and workforce readiness."

This event is Tuesday, Oct. 7, from 9-10:15 a.m. at The Partnership Tower. Find more information here.

Oct 7-9 — Tejano Tech Summit Week

LSA Global will present its fourth annual Tejano Tech Summit Week. The week will feature happy hours, networking opportunities and a founders dinner, along with talks from Mariela Salas, co-founder and partner of Alma Fund; Latina in Tech Houston, Blue People, The Magnolia Fund and others.

This event starts on Tuesday, Oct. 7, with most events taking place at the Ion. Find more information here.

Oct. 8 — Digital Health Institute Launch event

Celebrate the launch of the Houston Methodist-Rice Digital Health Institute, which aims to translate “innovative ideas into scalable solutions” with a focus on engineering, digital health and artificial intelligence. The event will feature presentations from Houston Methodist clinical researchers and Rice University faculty, a startup and industry panel and a venture capital investment panel.

This event is Wednesday, Oct. 8, from 8 a.m.-6:30 p.m. at Rice University's Duncan Hall - McMurtry Hall. Find more information here.

Oct. 8 — Founders Live Houston

Founders Live Houston returns this month with its happy hour pitch event. The global competition will select five Texas founders to present 99-second pitches and participate in a four-minute audience Q&A. Voters decide the winner.

This event is Thursday, Oct. 8, from 6-8 p.m. at the Ion. Find more information here.

Oct. 14 — NASA Stories at the Ion

Dina Contella, deputy manager of NASA’s International Space Station Program, will speak at this month's NASA Stories event. Contella will share insights from her career overseeing International Space Station operations, shaping Artemis missions and guiding real-time decisions in Mission Control.

This event is Tuesday, Oct. 14, from 8:30-10:30 a.m. at the Ion. Find more information here.

Oct. 16 — Impact Hub Houston Celebrates 7 Years in Community + Open Project Night

Celebrate seven years of Impact Hub Houston with a hands-on learning experience focused on hosting. The organization will share the tools, practices and hosting frameworks that have helped it build community and support local changemakers since it launched in 2018. Afterward, participate in Impact Hub's signature Open Project Night, where developers can come together to work on solutions for some of Houston’s most pressing issues.

These events are on Thursday, Oct. 16, at the Ion. The anniversary party is from 2-5 p.m. and Open Project Night begins at 5:30 p.m. Find more information here and here.

Oct. 16 — Future of Global Energy presented by Shell

Industry leaders, academia, and government will "explore the forces shaping the future of energy" at the Greater Houston Partnership's fifth annual Future of Global Energy Conference. Andy Karsner, chief strategist for energy and innovation at X, Alphabet’s Moonshot Factory, and a former U.S. Assistant Secretary of Energy, will present the keynote address. Speakers from companies Fervo Energy, S&P Global, Bechtel and others will also be featured on panels and in fireside chats. The event will culminate in Houston's first National Labs Day, where attendees can engage with leaders and technology specialists from Argonne National Laboratory, Brookhaven National Laboratory and other institutions.

This event is Thursday, Oct. 16, from 9 a.m.-3:30 p.m. Find more information here.

Oct. 23 — NASA Tech Talks

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, Oct. 23, from 6-7 p.m. at the Ion. Find more information here.

Oct. 25 — Ion Family Tech Festival

The Ion and partners will present the first-ever Ion Family Tech Fest this month, where families can participate in hands-on STEAM experiences.

This event is Saturday, Oct. 25, from 10 a.m.-1 p.m. at the Ion. Find more information here.